Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Change in Cash (2016 - 2025)

Historic Change in Cash for Standard Biotools (LAB) over the last 17 years, with Q3 2025 value amounting to -$29.2 million.

  • Standard Biotools' Change in Cash rose 5064.74% to -$29.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$79.9 million, marking a year-over-year decrease of 16079.03%. This contributed to the annual value of $116.3 million for FY2024, which is 49000.5% up from last year.
  • As of Q3 2025, Standard Biotools' Change in Cash stood at -$29.2 million, which was up 5064.74% from $7.7 million recorded in Q2 2025.
  • Standard Biotools' 5-year Change in Cash high stood at $235.8 million for Q1 2024, and its period low was -$62.6 million during Q3 2023.
  • Its 5-year average for Change in Cash is $3.3 million, with a median of -$14.2 million in 2022.
  • The largest annual percentage gain for Standard Biotools' Change in Cash in the last 5 years was 256025.64% (2022), contrasted with its biggest fall of 81132.56% (2022).
  • Over the past 5 years, Standard Biotools' Change in Cash (Quarter) stood at -$858000.0 in 2021, then soared by 2560.26% to $21.1 million in 2022, then crashed by 232.41% to -$28.0 million in 2023, then tumbled by 54.27% to -$43.1 million in 2024, then soared by 32.29% to -$29.2 million in 2025.
  • Its Change in Cash stands at -$29.2 million for Q3 2025, versus $7.7 million for Q2 2025 and -$15.3 million for Q1 2025.